Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 1209-1214 |
| Seitenumfang | 6 |
| Fachzeitschrift | European Journal of Clinical Nutrition |
| Jahrgang | 69 |
| Ausgabenummer | 11 |
| Publikationsstatus | Veröffentlicht - 1 Nov. 2015 |
Abstract
Background/Objectives:Lipid-lowering and anti-inflammatory effects have been individually described for tocotrienols (TTs) and polymethoxylated flavones (PMFs). This study investigated low-density lipoprotein-cholesterol (LDL-C)- and high-sensitivity C-reactive protein (hsCRP)-reducing effects of combined TT-PMF treatment in low doses in hypercholesterolemic individuals with subclinical inflammation.Subjects/Methods:In the double-blind, placebo-controlled study, 240 Caucasians with LDL-C ≥3.36 mmol/l and hsCRP ≥1 mg/l were enrolled and randomized into group S1 (12 mg/day TT and 103 mg/day PMF), group S2 (27 mg/day TT and 32 mg/day PMF) or placebo.Results:Twenty-three subjects dropped out of the study, 13 were excluded from the analysis because of lack of compliance. A total of 204 subjects per-protocol analysis were included. After 12 weeks of treatment, no significant differences in LDL-C levels (primary outcome) were observed between groups. LDL-C levels significantly decreased in all intervention groups (S1: -5.2%, S2: -4.8% and P: -4.2%). Total cholesterol and hsCRP (secondary outcome) did not change significantly.Conclusions:PMF-TT supplements had no effect beyond that of placebo on elevated LDL-C and hsCRP levels.
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Medizin (sonstige)
- Pflege (insg.)
- Ernährung und Diätetik
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: European Journal of Clinical Nutrition, Jahrgang 69, Nr. 11, 01.11.2015, S. 1209-1214.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - A combination of palm oil tocotrienols and citrus peel polymethoxylated flavones does not influence elevated LDL cholesterol and high-sensitivity C-reactive protein levels
AU - Schuchardt, Jan Philipp
AU - Heine, S.
AU - Hahn, A.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Background/Objectives:Lipid-lowering and anti-inflammatory effects have been individually described for tocotrienols (TTs) and polymethoxylated flavones (PMFs). This study investigated low-density lipoprotein-cholesterol (LDL-C)- and high-sensitivity C-reactive protein (hsCRP)-reducing effects of combined TT-PMF treatment in low doses in hypercholesterolemic individuals with subclinical inflammation.Subjects/Methods:In the double-blind, placebo-controlled study, 240 Caucasians with LDL-C ≥3.36 mmol/l and hsCRP ≥1 mg/l were enrolled and randomized into group S1 (12 mg/day TT and 103 mg/day PMF), group S2 (27 mg/day TT and 32 mg/day PMF) or placebo.Results:Twenty-three subjects dropped out of the study, 13 were excluded from the analysis because of lack of compliance. A total of 204 subjects per-protocol analysis were included. After 12 weeks of treatment, no significant differences in LDL-C levels (primary outcome) were observed between groups. LDL-C levels significantly decreased in all intervention groups (S1: -5.2%, S2: -4.8% and P: -4.2%). Total cholesterol and hsCRP (secondary outcome) did not change significantly.Conclusions:PMF-TT supplements had no effect beyond that of placebo on elevated LDL-C and hsCRP levels.
AB - Background/Objectives:Lipid-lowering and anti-inflammatory effects have been individually described for tocotrienols (TTs) and polymethoxylated flavones (PMFs). This study investigated low-density lipoprotein-cholesterol (LDL-C)- and high-sensitivity C-reactive protein (hsCRP)-reducing effects of combined TT-PMF treatment in low doses in hypercholesterolemic individuals with subclinical inflammation.Subjects/Methods:In the double-blind, placebo-controlled study, 240 Caucasians with LDL-C ≥3.36 mmol/l and hsCRP ≥1 mg/l were enrolled and randomized into group S1 (12 mg/day TT and 103 mg/day PMF), group S2 (27 mg/day TT and 32 mg/day PMF) or placebo.Results:Twenty-three subjects dropped out of the study, 13 were excluded from the analysis because of lack of compliance. A total of 204 subjects per-protocol analysis were included. After 12 weeks of treatment, no significant differences in LDL-C levels (primary outcome) were observed between groups. LDL-C levels significantly decreased in all intervention groups (S1: -5.2%, S2: -4.8% and P: -4.2%). Total cholesterol and hsCRP (secondary outcome) did not change significantly.Conclusions:PMF-TT supplements had no effect beyond that of placebo on elevated LDL-C and hsCRP levels.
UR - http://www.scopus.com/inward/record.url?scp=84947023223&partnerID=8YFLogxK
U2 - 10.1038/ejcn.2015.44
DO - 10.1038/ejcn.2015.44
M3 - Article
C2 - 25828621
AN - SCOPUS:84947023223
VL - 69
SP - 1209
EP - 1214
JO - European Journal of Clinical Nutrition
JF - European Journal of Clinical Nutrition
SN - 0954-3007
IS - 11
ER -